



(12) Translation of
European patent specification

(11) NO/EP 3098234 B1

NORWAY

(19) NO

(51) Int Cl.

A61P 5/06 (2006.01)

A61P 15/00 (2006.01)

A61K 38/00 (2006.01)

A61P 15/08 (2006.01)

A61P 5/10 (2006.01)

C07K 14/59 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.10.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.07.31
(86)	European Application Nr.	16179121.5
(86)	European Filing Date	2009.04.16
(87)	The European Application's Publication Date	2016.11.30
(30)	Priority	2008.04.25, EP, 08251528 2008.04.16, US, 45424 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP3045471, 2009.04.16
(73)	Proprietor	Ferring B.V., Polaris Avenue 144, 2132 JX Hoofddorp, Nederland
(72)	Inventor	COTTINGHAM, Ian, Ferring International Center S.A. Ch. de la Vergognausaz 50, 1162 Saint-Prex, Sveits PLAKSIN, Daniel, Ferring International Center S.A. Ch. de la Vergognausaz 50, 1162 Saint-Prex, Sveits WHITE, Richard, Boyd, -, deceased, USA
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SIALYLATION**

(56) References

Cited:

WO-A2-03/035686, WO-A1-2012/016576

DICKEY RICHARD P ET AL: "Highly purified human-derived follicle-stimulating hormone (Bravelle(R)) has equivalent efficacy to follitropin-beta (Follistim (R)) in infertile women undergoing in vitro fertilization", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, BIOMED CENTRAL LTD, GB, vol. 1, no. 1, 3 October 2003 (2003-10-03), pages 63, XP021009333, ISSN: 1477-7827, DOI: 10.1186/1477-7827-1-63

OLIJVE W ET AL: "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon).", MOLECULAR HUMAN REPRODUCTION MAY 1996, vol. 2, no. 5, May 1996 (1996-05-01), pages 371 - 382, XP002494717, ISSN: 1360-9947

JONES D ET AL: "High level expression of recombinant IgG in the human cell line PER.C6", BIOTECHNOLOGY PROGRESS, XX, XX, vol. 19, 1 January 2003 (2003-01-01), pages 163 - 168, XP002256988, ISSN: 8756-7938

FLACK M R ET AL: "Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM SEP 1994, vol. 79, no. 3, September 1994 (1994-09-01), pages 756 - 760, XP002494715, ISSN: 0021-972X

HORSMAN G ET AL: "A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon", HUMAN REPRODUCTION 2000 GB, vol. 15, no. 9, 2000, pages 1898 - 1902, XP002494716, ISSN: 0268-1161

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Rekombinant follikkelstimulerende hormon (rFSH) fremstilt eller uttrykt i en human
cellelinje, rFSH inkluderer α 2,3- og α 2,6-sialylering, hvori 10 % til 20 % av den totale
5 sialyleringen er α 2,6-sialylering, som inkluderer α 2,6-koblede sialinsyrer (α 2,6-sialylering)
tilveiebrakt av endogen sialyltransferaseaktivitet, og hvori den humane cellelinjen er
konstruert til å uttrykke en α 2,3-sialyltransferase.
2. Farmasøytisk sammensetning omfattende rFSH ifølge krav 1.
- 10 3. Farmasøytisk sammensetning ifølge krav 2, videre omfattende hCG og/eller LH.
4. Farmasøytisk sammensetning ifølge krav 2 eller krav 3 for anvendelse i
behandlingen av infertilitet.
- 15 5. Fremgangsmåte for produksjon av rFSH ifølge krav 1, omfattende et trinn med å
fremstille eller uttrykke rFSH i en human cellelinje.